基于人群的分析确定加拿大不列颠哥伦比亚省13价肺炎球菌结合疫苗对社区获得性肺炎的影响
该研究利用行政数据库诊断代码计算2000-2018年每月总体及年龄别社区获得性肺炎(CAP)发病率,采用负二项回归模型调整7价肺炎球菌结合疫苗程序,评估PCV13引入婴儿免疫规划8年后的影响。结果显示PCV13与0-2岁儿童CAP发病率下降相关(aIRR 0.91;95%CI 0.87-0.96),但其他年龄组未见显著下降。
要点
- PCV13婴儿免疫规划与0-2岁儿童CAP发病率下降相关(aIRR 0.91;95%CI 0.87-0.96)。
- 3-5岁、6-17岁、18-49岁、50-64岁及≥65岁人群CAP发病率未见显著下降。
- 其他年龄组CAP发病率未显著下降,需进一步研究CAP病因以制定有效预防方案。
核心结论
- PCV13婴儿免疫规划与疫苗目标年龄组CAP发病率下降存在时间关联,但其他年龄组CAP发病率未见显著下降,需进一步研究CAP病因以制定并实施有效预防方案。
研究设计与样本
- 基于人群的分析,利用行政数据库诊断代码计算2000-2018年每月总体及年龄别CAP发病率,采用负二项回归模型评估PCV13疫苗程序引入前后CAP发病率变化,并调整7价肺炎球菌结合疫苗程序。
主要发现
- PCV13婴儿免疫规划与0-2岁儿童CAP发病率下降相关(aIRR 0.91;95%CI 0.87-0.96)。
- 3-5岁人群总体CAP发病率未下降(aIRR 0.98;95%CI 0.93-1.04)。
- 6-17岁人群总体CAP发病率未下降(aIRR 1.02;95%CI 0.97-1.08)。
- 18-49岁人群总体CAP发病率未下降(aIRR 1.02;95%CI 0.98-1.05)。
- 50-64岁人群总体CAP发病率未下降(aIRR 1.07;95%CI 1.04-1.11),≥65岁人群总体CAP发病率未下降(aIRR 1.05;95%CI 1.02-1.08)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumonia is a leading cause of morbidity and mortality globally. We determined the impact of 13-valent pneumococcal conjugate vaccine (PCV13) use on community-acquired pneumonia (CAP) rates eight years after the vaccine was introduced in the infant immunization program. METHODS: Using diagnostic codes from administrative databases, we calculated the overall and age-specific CAP incidence per month (2000-2018). Changes in the CAP incidence before and after the PCV13 vaccine program introduction were evaluated using negative binomial regression model adjusting for 7-valent pneumococcal conjugate vaccine program. RESULTS: The PCV13 vaccine infant immunization program was associated with declining CAP incidence among children aged 0-2 years (adjusted Incidence Rate Ratio (aIRR): 0.91; 95% CI: 0.87-0.96). Overall CAP incidence did not decrease in those aged 3-5 years (0.98; 95% CI: 0.93-1.04), 6-17 years (1.02; 95% CI: 0.97-1.08), 18-49 years (1.02; 95% CI:0.98-1.05), 50-64 years (1.07; 95% CI: 1.04-1.11), ≥65 years (1.05; 95% CI:1.02-1.08). CONCLUSIONS: The PCV13 infant immunization program is temporally associated with a reduction in CAP incidence in vaccine target age group. However, no significant decrease in CAP incidence in other age groups warrants further study of the etiology of CAP to develop and implement effective prevention programs.
引用
- Vadlamudi NK, Patrick DM, Rose C, et al. A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada. Vaccine. 2022. PMID: 35012778. doi:10.1016/j.vaccine.2021.12.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。